LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02186 LUYE PHARMA

Trading 04-28 13:03:15

2.700

+0.030

+1.12%

High2.750	Low2.660	Vol8.32M
Open2.670	D1 Closing2.670	Amplitude3.37%
Mkt Cap10.79B	Tradable Cap10.79B	Total Shares4.00B
T/O22.57M	T/O Rate0.21%	Tradable Shares4.00B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"LUYE PHARMA","latestPrice":2.7,"timestamp":1777352493900,"preClose":2.67,"halted":0,"volume":8317000,"delay":0,"changeRate":0.011235955056179869,"floatShares":3995000000,"shares":3995000000,"eps":0.18222364792948093,"marketStatus":"Trading","change":0.03,"latestTime":"04-28 13:03:15","open":2.67,"high":2.75,"low":2.66,"amount":22572182,"amplitude":0.033708,"askPrice":2.7,"askSize":117000,"bidPrice":2.69,"bidSize":118000,"shortable":3,"etf":0,"ttmEps":0.18222364792948093,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777363800000},"marketStatusCode":2,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":2.67,"openAndCloseTimeList":[[1777339800000,1777348800000],[1777352400000,1777363200000]],"volumeRatio":1.011357,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186/wiki","defaultTab":"wiki","newsList":[{"id":"2630438266","title":"Shandong Boan says China CDE accepts Phase II trial application for BA1106-BA1104 combo in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2630438266","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630438266?lang=en_us&edition=fundamental","pubTime":"2026-04-26 18:31","pubTimestamp":1777199517,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology said China NMPA drug review center CDE accepted its Phase II clinical trial application for BA1106 combined with PD-1 inhibitor BA1104 in non-small cell lung cancer.Study targets driver gene-negative NSCLC as a first-line or second-line regimen.Boan plans to accelerate Phase II development following Phase I safety data showing mostly Grade 1-2 adverse events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nNDL8sTkzv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02186","BK1606","BK1583","BK1191","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100840496","title":"Luye Pharma launches first U.S. pharmacokinetic study for dual-acting VMAT2/Sigma-1R candidate LY03015","url":"https://stock-news.laohu8.com/highlight/detail?id=1100840496","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100840496?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:22","pubTimestamp":1776687761,"startTime":"0","endTime":"0","summary":"On 20 April 2026, Luye Pharma Group Ltd. disclosed the enrolment of the first volunteer in a U.S. pharmacokinetic (PK) bridging trial for LY03015, the company’s in-house-developed new molecular...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152735367","title":"LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1152735367","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152735367?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:14","pubTimestamp":1776687286,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that the first participant has been enrolled in the US pharmacokinetic (PK) bridging clinical trial for its self-developed new molecular entity, LY03015. This compound...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03015","06978","BK1606","BK1574","BK1161","BK1583","PK","159992","BK4181","BK4218","02186","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628228740","title":"Luye Pharma enrolls first subject in US PK bridging trial of LY03015","url":"https://stock-news.laohu8.com/highlight/detail?id=2628228740","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628228740?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:03","pubTimestamp":1776686628,"startTime":"0","endTime":"0","summary":"Luye Pharma enrolled first subject in a U.S. pharmacokinetic bridging study of LY03015, an investigational VMAT2 inhibitor and sigma-1 receptor agonist for tardive dyskinesia and Huntington’s disease.Results have not been presented; study is designed to generate safety, tolerability, and pharmacokinetic evidence to guide dose selection for planned U.S. Phase II and Phase III trials.Trial is open-label, single-dose, parallel-group in healthy Chinese and Caucasian adults, positioning LY03015 for cross-population development in U.S. regulatory pathway.Program aims to support a differentiated profile versus existing VMAT2-only therapies by combining symptom control with potential longer-lasting benefit.Luye expects to complete a Phase II trial in China soon, supporting parallel development across China and U.S. CNS pipelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbYzcr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","02186","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627268263","title":"Luye Pharma Enrolls First Patient in Phase 2 China Trial of Alzheimer's Psychosis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627268263","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627268263?lang=en_us&edition=fundamental","pubTime":"2026-04-16 11:32","pubTimestamp":1776310364,"startTime":"0","endTime":"0","summary":"Luye Pharma  said it enrolled the first patient in a Phase 2 clinical trial in China for its investigational drug LY03017, according to a Wednesday Hong Kong bourse filing.Shares of the pharma company fell over 2% in late-morning trade Thursday.The drug is being tested for the treatment of psychosis associated with Alzheimer's disease.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1191","02186","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153591250","title":"CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1153591250","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153591250?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:23","pubTimestamp":1776302616,"startTime":"0","endTime":"0","summary":"CATL (03750) plans to invest RMB 30 billion to establish a wholly-owned subsidiary for building a new energy mineral platform. Meig Smart Technology (03268) intends to invest RMB 300 million in an AI...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f2ca9b0f4a170b1d9ddb723b50e84ead","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2424517915.HKD","LU0797268264.HKD","LU0675040207.SGD","LU1993786604.SGD","SG9999001093.SGD","LU1997245094.SGD","LU1961090484.USD","LU2495084118.USD","LU0169518387.USD","LU0348805143.USD","IE00B29SXG58.USD","LU0302445910.USD","LU0516422440.USD","LU0634319403.HKD","LU0672654166.SGD","LU1969619763.USD","XIACY","LU0594300419.USD","LU0509642566.USD","IE00BPRC5H50.USD","LU0823413660.USD","BK1618","BK1166","HK0000286598.CNH","LU0048575426.USD","LU0348735423.USD","002352","LU1048588211.SGD","LU0164872284.USD","LU2449936058.SGD","LU0210526637.USD","IE00BZ199S13.USD","LU1769817179.HKD","LU2476274720.SGD","LU1831875114.USD","BK4519","LU0823039010.USD","601111","LU1880383366.USD","LU0449515922.USD","LU2294711473.HKD","LU1515016050.SGD","LU0823437842.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0314109678.HKD","LU0259732245.USD","BK1116","LU0823397103.USD","00300","300433","LU1146622755.USD","LU1323998911.USD","LU2348773727.SGD","LU1868838027.USD","LU0084288322.USD","LU0405327148.USD","LU1960683339.HKD","LU0516422952.EUR","HK0000181138.USD","LU1048596156.SGD","LU0327786744.USD","LU2477742899.HKD","HK0000181112.HKD","SG9999001903.USD","LU0181495838.USD","CCOZY","LU0821914370.USD","LU1303224171.USD","LU1997244956.HKD","LU2275660780.HKD","LU0106252389.USD","LU1934453819.USD","LU0106259558.USD","06613","BK4588","LU0107464264.USD","LU2045819591.USD","LU0499858602.USD","LU0039217434.USD","LU1023057109.AUD","LU2087589342.USD","LU0516423091.SGD","LU0320764755.SGD","LU0164880469.USD","01810","LU0417516902.SGD","LU0441854154.USD","LU0048580855.USD","LU0132412106.USD","LU0188438112.USD","688331","LU1481107354.HKD","300750","SG9999014674.SGD","06936","LU3063872942.SGD","LU0823426480.USD","LU2506952410.USD","01138","00753","LU0345776255.USD","SGXZ49509284.SGD","08279","LU0043850808.USD","02038","LU0359202008.SGD","LU2506952253.HKD","LU2125910500.SGD","LU1807302812.USD","SG9999001689.USD","LU0164865239.USD","SG9999001846.SGD","SG9999000327.SGD","IE00B5MMRT66.SGD","LU1868837565.USD","LU2097828805.USD","IE0003795394.USD","LU0047713382.USD","LU1242518931.SGD","FXCNY","LU2249611893.SGD","BK1535","LU1152091168.USD","LU0611395673.USD","SG9999000459.SGD","LU0700851271.USD","LU2039709279.SGD","LU1781817850.SGD","LU0823040885.USD","IE0034224299.USD","LU1861219969.SGD","LU2580892862.HKD","BK1521","LU0143863198.USD","LU0594300179.USD","LU2153591404.USD","LU2298064838.USD","LU0593848301.USD","LU2360107325.USD","LU0140636845.USD","LU2506951792.HKD","LU1255011170.USD","IE0003851619.USD","LU0979878070.USD","600026","LU2506952337.HKD","LU0918141705.HKD","BK1610","LU1051769294.HKD","LU0211977185.USD","LU0029875118.USD","LU1956131251.USD","LU0231483743.USD","LU1064130708.USD","IE00B8HQ1Z84.USD","LU0607220059.USD","LU0651947912.USD","LU0605514214.HKD","HK0000165453.HKD","LU0456846285.SGD","LU0143863784.USD","BK1607","601898","LU0828237940.HKD","LU0312595415.SGD","LU1064131003.USD","LU2328871848.SGD","LU2476274308.USD","LU0149721374.USD","LU2148510915.USD","LU2097828474.EUR","02186","LU2294711713.HKD","LU1282648689.USD","81810","BK1523","LU0320764599.SGD","LU1242518857.USD","LU0531971595.HKD","IE00B8L5B284.USD","BK1502","BK1575","LU2242644610.SGD","LU2125910849.SGD","LU2348774022.SGD","LU0067412154.USD","LU0326950275.SGD","06656","LU0348816934.USD","LU2580892789.USD","LU0307460666.USD","LU2257852520.SGD","BK1506","MIUmain","LU0516423174.USD","LU0823414478.USD","LU0650527681.SGD","IE0032431581.USD","00670","LU2153592121.USD","LU0359201612.USD","LU2399975544.HKD","LU0823397285.USD","LU0054450605.USD","LU0051755006.USD","BK1615","LU1813983027.USD","LU0049853897.USD","LU1979443071.USD","03908","LU2097828557.USD","LU1720050803.USD","SBHMY","LU0149534421.HKD","BK1589","002881","LU2097828714.EUR","LU0823041008.USD","LU0828237510.HKD","LU0117841782.USD","LU1769817096.USD","LU0192582467.USD","01093","LU0214875030.USD","LU0871576103.HKD","LU1794554557.SGD","LU0540923850.HKD","LU0918141887.USD","LU0543330483.HKD","LU0370786039.SGD","03268","LU0449509016.USD","02298","LU0359201885.HKD","LU0708995583.HKD","LU1861214812.USD","LU1039395188.USD","BK1193","LU1820825898.SGD","601995","SG9999002828.SGD","LU2289578879.USD","SGXZ81163826.USD","SG9999003461.SGD","LU1770036033.HKD","LU1188198961.HKD","LU0572944931.SGD","LU0463099449.HKD","LU0251143458.SGD","BK4585","LU0502904849.HKD","02465","LU0228659784.USD","LU0261950470.USD","LU0326948709.USD","LU0516422366.SGD","LU0651946864.USD","LU0505663152.USD","LU2778985437.USD","LU0823426308.USD","LU0348825331.USD","LU0501845795.SGD","MIUmain","LU1997245177.USD","01898","LU2097828631.EUR","LU1721428347.USD","LU1102505929.USD","09995","LU0823413587.USD","LU1251922891.USD","LU0345775950.USD","LU1051768304.USD","LU0499858438.USD","LU0455707207.USD","LU0880133367.SGD","LU0165289439.USD","LU2226246903.HKD","LU0405327494.USD","LU0052750758.USD","LU0561508036.HKD","LU1981816686.USD","LU1939255532.USD","LU0588546209.SGD","LU2357125470.USD","LU0011963245.USD","LU0828238088.HKD","LU0106959298.USD","LU1770034418.SGD","BK4526","LU0328353924.USD","LU1655091616.SGD","LU0531970944.HKD","LU2238339852.HKD","LU1152091754.HKD","LU1978683503.SGD","LU0254981946.USD","LU0456827905.SGD","IE00BD6J9T35.USD","603906","LU1580142542.USD","LU0469268626.HKD","02245","LU0124384867.USD","03750","LU0128522157.USD","LU1880383440.USD","LU0244354667.USD","000333","LU1719994722.HKD","BK4141","LU0724618433.USD","01177","LU0823414551.USD","LU0269904917.USD","LU1328277881.USD","LU0417516738.SGD","SG9999002463.SGD","BK1149","IE00B3M56506.USD","LU0235996351.USD","600115","LU1105468828.SGD","LU2298322129.HKD","BK0224","LU1808992512.USD","02556","LU2152927971.USD","LU0348814723.USD","LU0348827113.USD","HXXD.SI","LU0072462343.USD","EVS.SI","LU0823038988.USD","LU0048388663.USD","LU1102505762.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130423128","title":"LUYE PHARMA's Innovative Drug LY03017 Enrolls First Patient in Chinese Phase II Trial for Alzheimer's Disease Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1130423128","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130423128?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:08","pubTimestamp":1776258507,"startTime":"0","endTime":"0","summary":"LUYE PHARMA has announced that the first patient has been enrolled in a Phase II clinical trial in China for its self-developed innovative drug, LY03017, which is intended for the treatment of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1191","02186","159992","06978","BK1583","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182767326","title":"Luye Pharma initiates China Phase II trial of LY03017 targeting Alzheimer’s disease-related psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=1182767326","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182767326?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:03","pubTimestamp":1776258208,"startTime":"0","endTime":"0","summary":"Hong Kong–listed Luye Pharma Group Ltd. enrolled the first subject in a randomized, double-blind, placebo-controlled Phase II trial of its in-house candidate LY03017 for Alzheimer’s disease-related...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627742632","title":"A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2627742632","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627742632?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:07","pubTimestamp":1776182827,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in China for LY03020, a dual TAAR1 and 5-HT2CR agonist targeting schizophrenia.\nSee our latest analysis for Luye Pharma Group.\nThe LY03020 trial update comes as Luye Pharma Group’s share price sits at HK$2.89, with a 30-day share price return of 18.93% contrasting with a 90-day share price decline of 3.99%. The 1-year total shareholder return of 55.38% stands against a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-as-ly03020-en","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-as-ly03020-en","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02186","BK1191","BK1606","BK1583","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133445978","title":"LUYE PHARMA Shares Climb Nearly 3% in Morning Session as Self-Developed Drug LY03020 Enrolls First Patient in Chinese Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1133445978","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133445978?lang=en_us&edition=fundamental","pubTime":"2026-04-14 12:02","pubTimestamp":1776139339,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) rose nearly 3% in morning trading. At the time of writing, the stock was up 2.52%, trading at HK$2.85, with a turnover of HK$53.236 million. The increase follows a recent...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4588","159992","VXUS","BK1574","BK1161","BK1583","BK4585","02186","BK1606","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137297772","title":"UBS Increases Stake in LUYE PHARMA by 13.95 Million Shares at HK$2.85 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1137297772","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137297772?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:26","pubTimestamp":1776079572,"startTime":"0","endTime":"0","summary":"On April 2, UBS purchased an additional 13.9545 million shares of LUYE PHARMA (02186) at HK$2.8547 per share, involving a total consideration of approximately HK$39.84 million. Following this...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1606","BK1191","02186","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104880672","title":"LUYE PHARMA's Innovative Drug LY03020 Enrolls First Patient in Chinese Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1104880672","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104880672?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:46","pubTimestamp":1775659592,"startTime":"0","endTime":"0","summary":"LUYE PHARMA has announced that the first patient has been enrolled in the China Phase II clinical trial for its self-developed innovative drug, LY03020. LY03020 is the world's first dual-target...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03020","02186","06978","BK1191","BK1583","159992","BK1606","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625940854","title":"Luye Pharma enrolls first patient in China Phase II trial of LY03020 schizophrenia drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625940854","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625940854?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:30","pubTimestamp":1775658646,"startTime":"0","endTime":"0","summary":"Luye Pharma enrolled first patient in China Phase II trial of LY03020, an in-house antipsychotic candidate for acute schizophrenia.No clinical results were presented; trial is designed to generate efficacy, safety, and pharmacokinetic readouts to guide dose selection.Development plan positions LY03020 as a next-generation option aimed at improving symptom control while reducing side-effect burden versus older antipsychotics.Program also cleared to start US clinical testing, supporting parallel China-US development in Luye Pharma’s central nervous system pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL6HQMQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02186","BK1606","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186791001","title":"Luye Pharma Maintains Stable Share Base in March 2026; USD 180 Million Convertible Bonds Allow Up to 288.79 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1186791001","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186791001?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:42","pubTimestamp":1775655766,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. (Luye Pharma) reported no changes to its equity structure for the month ended 31 March 2026, according to its monthly return filed with Hong Kong Exchanges and Clearing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625629416","title":"Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2625629416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625629416?lang=en_us&edition=fundamental","pubTime":"2026-04-06 06:02","pubTimestamp":1775426578,"startTime":"0","endTime":"0","summary":"As global markets navigate geopolitical tensions and energy market volatility, Asian small-cap stocks are drawing attention for their potential amidst these dynamic conditions. With improving domestic activity signals in China and strategic economic maneuvers in India, the region presents unique opportunities for investors seeking growth beyond the traditional large-cap landscape. Identifying promising small-cap stocks involves looking at companies that demonstrate resilience and adaptability...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4012000-choice2-main-header/1585186808051","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4012000-choice2-main-header/1585186808051"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/automobiles/szse-301225/hengbo-holdingsltd-shares/news/undiscovered-gems-in-asia-including-3-promising-small-cap-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/automobiles/szse-301225/hengbo-holdingsltd-shares/news/undiscovered-gems-in-asia-including-3-promising-small-cap-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","02186","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625150576","title":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2625150576","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625150576?lang=en_us&edition=fundamental","pubTime":"2026-04-04 22:18","pubTimestamp":1775312322,"startTime":"0","endTime":"0","summary":"Why Luye Pharma’s latest earnings matter for investors\nLuye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend.\nThe company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1606","DCF","BK1191","02186","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167334961","title":"Stock Track | LUYE PHARMA Stock Soars 5.17% in Intraday Trading After Reporting Strong 2025 Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1167334961","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167334961?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:01","pubTimestamp":1775095310,"startTime":"0","endTime":"0","summary":"LUYE PHARMA's stock surged 5.17% during intraday trading on Thursday, reflecting strong investor sentiment.The sharp rise follows the company's release of its 2025 earnings report, which showed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141323222","title":"LUYE PHARMA Shares Surge Nearly 5% on Strong 2025 Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1141323222","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141323222?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:59","pubTimestamp":1775095162,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) rose nearly 5% in Hong Kong trading. At the time of writing, the stock was up 3.69% to HK$2.81, with a trading volume of HK$105 million. The catalyst for the movement was the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","VXUS","BK1606","02186","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379597","title":"Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379597","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623379597?lang=en_us&edition=fundamental","pubTime":"2026-03-31 10:18","pubTimestamp":1774923480,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  booked 618.7 million yuan in attributable profit for 2025, rising 31% from 471.9 million yuan in 2024, according to a Hong Kong bourse filing Tuesday.Earnings per share were 0.1250 yuan, compared with 0.1254 yuan in the prior year.Revenue rose 4.1% year on year to 6.31 billion yuan, figures showed.The company did not declare a final dividend for the year.Shares of the company were up nearly 3% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02186","BK1191","BK1606","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623359376","title":"BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2623359376","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623359376?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:40","pubTimestamp":1774921232,"startTime":"0","endTime":"0","summary":"BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLNMarch 31 (Reuters) - Luye Pharma 2186.HK: LUYE PHARMA GROUP FY NET INCOME ATTRIBUTABLE RMB 618.7 MILLIONLUYE PHARMA GROUP FY REVENUE RMB 6,308.4 MILLIONFurther company coverage: [ ] ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXB82ACC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1606","02186"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.0532},{"period":"1month","weight":0.1079},{"period":"3month","weight":-0.0793},{"period":"6month","weight":-0.1442},{"period":"1year","weight":0.335},{"period":"ytd","weight":-0.0255}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.024212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.016158},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.022436},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003135},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.0086},{"month":6,"riseRate":0.363636,"avgChangeRate":0.035296},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018026},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.044846},{"month":9,"riseRate":0.583333,"avgChangeRate":0.045957},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012685}],"exchange":"SEHK","name":"LUYE PHARMA","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUYE PHARMA,02186,LUYE PHARMA股票,LUYE PHARMA股票老虎,LUYE PHARMA股票老虎国际,LUYE PHARMA行情,LUYE PHARMA股票行情,LUYE PHARMA股价,LUYE PHARMA股市,LUYE PHARMA股票价格,LUYE PHARMA股票交易,LUYE PHARMA股票购买,LUYE PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}